An RNAi in Silico Approach to Find an Optimal ShRNA Cocktail Against HIV-1

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2010 Dec 22

PMID 21172023

Citations 3

Authors

Maria C Mendez-Ortega

Silvia Restrepo

Luis M Rodriguez-R

Ivan Perez

Juan C Mendoza

Andres P Martinez

Roberto Sierra

Gloria J Rey-Benito

Affiliations

Soon will be listed here.

Abstract

Background: HIV-1 can be inhibited by RNA interference in vitro through the expression of short hairpin RNAs (shRNAs) that target conserved genome sequences. In silico shRNA design for HIV has lacked a detailed study of virus variability constituting a possible breaking point in a clinical setting. We designed shRNAs against HIV-1 considering the variability observed in naïve and drug-resistant isolates available at public databases.

Methods: A Bioperl-based algorithm was developed to automatically scan multiple sequence alignments of HIV, while evaluating the possibility of identifying dominant and subdominant viral variants that could be used as efficient silencing molecules. Student t-test and Bonferroni Dunn correction test were used to assess statistical significance of our findings.

Results: Our in silico approach identified the most common viral variants within highly conserved genome regions, with a calculated free energy of ≥ -6.6 kcal/mol. This is crucial for strand loading to RISC complex and for a predicted silencing efficiency score, which could be used in combination for achieving over 90% silencing. Resistant and naïve isolate variability revealed that the most frequent shRNA per region targets a maximum of 85% of viral sequences. Adding more divergent sequences maintained this percentage. Specific sequence features that have been found to be related with higher silencing efficiency were hardly accomplished in conserved regions, even when lower entropy values correlated with better scores. We identified a conserved region among most HIV-1 genomes, which meets as many sequence features for efficient silencing.

Conclusions: HIV-1 variability is an obstacle to achieving absolute silencing using shRNAs designed against a consensus sequence, mainly because there are many functional viral variants. Our shRNA cocktail could be truly effective at silencing dominant and subdominant naïve viral variants. Additionally, resistant isolates might be targeted under specific antiretroviral selective pressure, but in both cases these should be tested exhaustively prior to clinical use.

Citing Articles

Microscale Symmetrical Electroporator Array as a Versatile Molecular Delivery System.

Ouyang M, Hill W, Lee J, Hur S Sci Rep. 2017; 7:44757.

PMID: 28317836 PMC: 5357946. DOI: 10.1038/srep44757.

Post-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virus.

Mendez C, Ahlenstiel C, Kelleher A World J Virol. 2015; 4(3):219-44.

PMID: 26279984 PMC: 4534814. DOI: 10.5501/wjv.v4.i3.219.

A comparison of multiple shRNA expression methods for combinatorial RNAi.

McIntyre G, Arndt A, Gillespie K, Mak W, Fanning G Genet Vaccines Ther. 2011; 9(1):9.

PMID: 21496330 PMC: 3098768. DOI: 10.1186/1479-0556-9-9.

References

Boden D, Pusch O, Lee F, Tucker L, Ramratnam B . Human immunodeficiency virus type 1 escape from RNA interference. J Virol. 2003; 77(21):11531-5. PMC: 229317. DOI: 10.1128/jvi.77.21.11531-11535.2003. View

Boyle B, Cohen C, DeJesus E, Elion R, Frank I, Moyle G . Update on antiretroviral therapy: the 15th CROI. AIDS Read. 2008; 18(5):273-8, C3. View

Colin L, Van Lint C . Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009; 6:111. PMC: 2797771. DOI: 10.1186/1742-4690-6-111. View

Kim H, Perelson A . Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol. 2006; 2(10):e135. PMC: 1599767. DOI: 10.1371/journal.pcbi.0020135. View

Zhou H, Zeng X . Energy profile and secondary structure impact shRNA efficacy. BMC Genomics. 2009; 10 Suppl 1:S9. PMC: 2709270. DOI: 10.1186/1471-2164-10-S1-S9. View

Naito Y, Nohtomi K, Onogi T, Uenishi R, Ui-Tei K, Saigo K . Optimal design and validation of antiviral siRNA for targeting HIV-1. Retrovirology. 2007; 4:80. PMC: 2204037. DOI: 10.1186/1742-4690-4-80. View

Mcintyre G, Groneman J, Yu Y, Jaramillo A, Shen S, Applegate T . 96 shRNAs designed for maximal coverage of HIV-1 variants. Retrovirology. 2009; 6:55. PMC: 2698899. DOI: 10.1186/1742-4690-6-55. View

Boasso A, Shearer G . Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol. 2007; 126(3):235-42. PMC: 2275778. DOI: 10.1016/j.clim.2007.08.015. View

Marchler-Bauer A, Anderson J, Derbyshire M, DeWeese-Scott C, Gonzales N, Gwadz M . CDD: a conserved domain database for interactive domain family analysis. Nucleic Acids Res. 2006; 35(Database issue):D237-40. PMC: 1751546. DOI: 10.1093/nar/gkl951. View

10.

Dahl V, Josefsson L, Palmer S . HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral Res. 2009; 85(1):286-94. DOI: 10.1016/j.antiviral.2009.09.016. View

11.

Altschul S, Gish W, Miller W, Myers E, Lipman D . Basic local alignment search tool. J Mol Biol. 1990; 215(3):403-10. DOI: 10.1016/S0022-2836(05)80360-2. View

12.

Liu Y, Jasmijn von Eije K, Schopman N, Westerink J, Brake O, Haasnoot J . Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther. 2009; 17(10):1712-23. PMC: 2835024. DOI: 10.1038/mt.2009.176. View

13.

Rodriguez-Arenas M, Jarrin I, Del Amo J, Iribarren J, Moreno S, Viciana P . Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2006; 22(8):715-23. DOI: 10.1089/aid.2006.22.715. View

14.

Cohen M, Hellmann N, Levy J, DeCock K, Lange J . The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest. 2008; 118(4):1244-54. PMC: 2276790. DOI: 10.1172/JCI34706. View

15.

Basu V, Song M, Gao L, Rigby S, Hanson M, Bambara R . Strand transfer events during HIV-1 reverse transcription. Virus Res. 2008; 134(1-2):19-38. DOI: 10.1016/j.virusres.2007.12.017. View

16.

Hubner A, Kruhoffer M, Grosse F, Krauss G . Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural RNA. J Mol Biol. 1992; 223(3):595-600. DOI: 10.1016/0022-2836(92)90975-p. View

17.

Back N, Nijhuis M, Keulen W, Boucher C, Oude Essink B, van Kuilenburg A . Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 1996; 15(15):4040-9. PMC: 452124. View

18.

Tilesi F, Fradiani P, Socci V, Willems D, Ascenzioni F . Design and validation of siRNAs and shRNAs. Curr Opin Mol Ther. 2009; 11(2):156-64. View

19.

Brake O, Konstantinova P, Ceylan M, Berkhout B . Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006; 14(6):883-92. DOI: 10.1016/j.ymthe.2006.07.007. View

20.

Silverman A, Kool E . RNA probes of steric effects in active sites: high flexibility of HIV-1 reverse transcriptase. J Am Chem Soc. 2007; 129(35):10626-7. DOI: 10.1021/ja072791b. View